Shares of Repros Therapeutics Inc RPRX, a nano-cap biopharmaceutical company that focuses on the treatment of hormonal and reproductive system disorders, is surging higher by 60 percent.
Repros Therapeutics reported after Tuesday's close that patients receiving 6 and 12 mg doses of Proellex achieved significant reduction in excessive menstrual bleeding, the key symptom of uterine fibroids. The findings were part of a small Phase 2b study.
Repros Therapeutics believes Prollex "represents a significant advantage over GnRH agonists and antagonists in the treatment of uterine fibroids."
The company added it plans on requesting an end of Phase 2 meeting with the U.S. Food and Drug Administration and will discuss plans for a Phase 3 trial.
The stock traded recently at $0.81, up 59 percent in the pre-market session.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.